Effectiveness of alpha-interferon therapy and bcr-abl transcripts in patients with chronic myeloid leukemia (CML)

V. I. Petukhov, I. L. Strozha, A. V. Zhilevich, D. K. Bondare, A. Line, E. K. Yantsevich, A. Tsimanis, R. A. Treimane, A. R. Kruminya

Research output: Contribution to journalArticlepeer-review


Polymerase chain reaction (PCR) was used to study bcr-abl transcripts in 36 CML patients. 13 of them have received recombinant or natural alpla-interferon, 15 were treated with myelosan or hydroxyurea and 8 - combination of cytostatics. Rearrangement types b3a2, b2a2 and e1a2 occurred in 22, 5 and 5 out of 36 patients, respectively. Two patients displayed coexpression b3a2+b2a2, and one - b3a2+e1a2. Gene rearrangement type remained unidentified in one case. The majority of patients with new-onset blast transformation (in 6 of 8) had transcript e1a2. Alpha-interferon therapy produced the largest number of complete remissions, cytogenetic among them (reduction of pH′-clone by 15-87%), in patients with the rearrangement type b3a2. The least therapeutic response was noted in patients with coexpression b3a2+b2a2. Cytogenetic response to alpha-interferon therapy was as a rule absent in patients with type b2a2. No significant correlation was registered between the type of bcr-abl rearrangement and duration of CML chronic phase, survival, clinical course and/or hematological parameters.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalGematologiya i Transfusiologiya
Issue number1
Publication statusPublished - 1999
Externally publishedYes


  • Alpha-interferon
  • Bcr-abl transcript
  • Chronic myeloid leukemia
  • Therapy

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database


Dive into the research topics of 'Effectiveness of alpha-interferon therapy and bcr-abl transcripts in patients with chronic myeloid leukemia (CML)'. Together they form a unique fingerprint.

Cite this